To this aim, we produced the anti-PD-1 mAb with IgG4 isotype, and anti-CTLA-4 mAb with IgG1 isotype, in order to better compare them to Nivolumab and Ipilimumab, IgG4 and IgG1, respectively, to evaluate their isotype-independent effects on tumor cells. The gene discussed is CTLA4; the disease is neoplasm.